George Town, Cayman Islands February 06, 2025 --(PR.com)-- Legacy Pharma Inc. SEZC (“Legacy Pharma” or the “Company”), a specialty pharmaceutical company, announced the completion of the acquisition of InterMune, Inc. (“InterMune”) and the intellectual property rights to Esbriet® (pirfenidone) in the United States from Genentech, ?a member of the Roche Group?. This strategic acquisition underscores Legacy Pharma's commitment to expanding its portfolio of high-quality pharmaceutical products and enhancing patient access to innovative treatments.

Esbriet®, a medication used to treat idiopathic pulmonary fibrosis (IPF), has shown significant promise in improving the lives of patients with this chronic and life-threatening lung disease. With this acquisition, Legacy Pharma aims to ensure the continued availability and distribution of Esbriet® to patients? ?across the United States.? Genentech will continue to provide access to Esbriet® in the United States until the completion of the business transfer. Furthermore, Roche will retain commercial rights in all other territories.?

"We are excited to acquire InterMune and add Esbriet® to our portfolio of essential medications," said Mark Thompson, CEO of Legacy Pharma. "This acquisition aligns with our mission to provide patients with access to innovative and life-changing treatments.????"

Legacy Pharma Inc. SEZC is dedicated to maintaining the highest standards of quality and customer service. The Company's acquisition of InterMune and ???certain?? ?U.S. intellectual property rights to Esbriet® is a testament to its ongoing commitment to expanding its portfolio of legacy pharmaceutical products and strengthening its collaboration with key partners in the industry, such as ?Genentech?.

???About Legacy Pharma Inc. SEZC??? ???

Legacy Pharma Inc. SEZC is a pharmaceutical company focused on distributing established prescription pharmaceutical products. The Company is committed to ensuring that in-demand brands remain available for distribution to patients who need them. For more information about Legacy Pharma Inc. SEZC and its product offerings, please visit www.legacypharmainc.com.

??For further information?, contact: [email protected]

Contact Information:
Legacy Pharma Inc. SEZC
Mark Thompson
289-259-7909
Contact via Email
legacypharmainc.com

Read the full story here: https://www.pr.com/press-release/930210

Press Release Distributed by PR.com



Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]